The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg Seroconversion

@article{Fung2009TheDO,
  title={The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg Seroconversion},
  author={James Fung and Ching-lung Lai and Yasuhito Tanaka and Masashi Mizokami and John Chi-hang Yuen and Danny Ka-ho Wong and Man-fung Yuen},
  journal={The American Journal of Gastroenterology},
  year={2009},
  volume={104},
  pages={1940-1946}
}
OBJECTIVES:The aim of this study was to compare the virological and biochemical relapse rates in Asian chronic hepatitis B patients with lamivudine-induced hepatitis B e antigen (HBeAg) seroconversion, between those who stopped therapy after HBeAg seroconversion and those who continued to receive lamivudine.METHODS:All patients with lamivudine-induced HBeAg seroconversion were included. Patients who stopped lamivudine after HBeAg seroconversion (n=22) were compared with 79 patients who… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.

Liver international : official journal of the International Association for the Study of the Liver • 2018

References

Publications referenced by this paper.
Showing 1-10 of 26 references

A comparison of entecavir and lamivudine for HBeAg - positive chronic hepatitis B

TT Chang, RG Gish, R deMan
N Engl J Med • 2006

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2006

Similar Papers

Loading similar papers…